Clinical Trials Logo

Clinical Trial Summary

While the number of kidney transplants is increasing worldwide every year, there is a clear imbalance between the high number of patients in the waiting list and those receiving a transplant and importantly, among waitlist patients there is a progressively higher number of highly sensitised patients that have very low or even no chance to receive a compatible organ. These patients remain for very long periods of time on dialysis therapy, having lower quality of life, lower life expectancy and produce higher health-related costs. Unfortunately, current desensitization therapies have shown very poor success and patients usually lose these grafts very fast if transplanted across a positive cross-match. Therefore, there is an urgent need for novel desensitization strategies capable of overcoming this immunological barrier and allow an increasing number of patients to receive a HLA-compatible kidney allograft.This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA or TGI ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.


Clinical Trial Description

This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA or TGI ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05145296
Study type Interventional
Source University Hospital, Grenoble
Contact Paolo Malvezzi, MD
Phone 0476765460
Email pmalvezzi@chu-grenoble.fr
Status Recruiting
Phase N/A
Start date January 19, 2022
Completion date November 2, 2025

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04818190 - DIEP (Deep Inferior Epigastric Artery Perforator) Flap Sensory Recovery Following Neurotization N/A
Completed NCT05079607 - Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers N/A
Recruiting NCT06204510 - Effects of Complex Decongestive Therapy on Proprioception, Balance and Tactile Sense N/A
Completed NCT06047704 - The Effect of State and Trait Anxiety on Pain-pressure Threshold
Enrolling by invitation NCT01473823 - Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood N/A
Completed NCT04498676 - 50 Human Subject Repeat Insult Patch Test N/A
Recruiting NCT03223844 - Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release N/A
Not yet recruiting NCT05704218 - Hypersensitivity Pneumonitis of Domestic Origin N/A
Completed NCT04510675 - Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT N/A